9-Iodo-1-nonanol | CAS:76334-30-0

We serve 9-Iodo-1-nonanol CAS:76334-30-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
9-Iodo-1-nonanol

Chemical Name:9-Iodo-1-nonanol
CAS.NO:76334-30-0
Synonyms:9-Iodo-1-nonanol
9-Iodo-1-nonanol
9-Iodononan-1-ol
Molecular Formula:C9H19IO
Molecular Weight:270.15100
 
Specification:
Appearance:Colorless to yellow transparent liquid
Assay:≥98.0%
Moisture:≤0.3%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 9-Iodo-1-nonanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,9-Iodononan-1-ol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,9-Iodo-1-nonanol Use and application,9-Iodononan-1-ol technical grade,usp/ep/jp grade.


Related News: Catalent’s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management.4-Chloro-7-(3-chloropropoxy)-6-methoxyquinoline-3-carbonitrile manufacturer The downstream industry of the pharmaceutical intermediate industry is mainly the production of APIs, and the relationship between APIs and preparations is in the upstream and downstream industry chain. The consumer demand for downstream preparations will directly affect the demand for APIs.4-CHLORO-α-(METHYLAMINO)BENZENE ACETIC ACID supplier The downstream industry of the pharmaceutical intermediate industry is mainly the production of APIs, and the relationship between APIs and preparations is in the upstream and downstream industry chain. The consumer demand for downstream preparations will directly affect the demand for APIs.4-chloro-2,3-dihydroisoindol-1-one vendor Over the past twelve months, the collaboration team has worked to optimize its processes for making T cells from iPSCs, and has now shown the production of pure T-lymphocytes consisting of both CD8+ and CD4+ T cells having a global gene expression profile that is highly-similar to primary T cells based on a principal component analysis.Doctors have seen fever, coughing and breathing difficulties, which are all to be expected.